LLY Options Show Bullish Setup at $1000 Call Amid Strong Earnings and Strategic Moves: Trade Ideas for April 2nd

• Eli Lilly (LLY) opens lower at 933.5 today after a sharp intraday swing from 957.69 to 930.02
• Options market shows a heavy call OI buildup at the $1000 strike for Friday
• Recent news includes a $6.5B acquisition, FDA fast-track approval, and a new $2B buyback

Today’s price action in Eli Lilly has been anything but calm. After an emotional opening at 946.6, the stock dropped sharply, finishing the day at 933.5—a -2.2% drop from the previous close. The market is clearly reacting to both fundamental news and positioning in the options market. But what’s really interesting is the OTM call options that are quietly building up volume, especially at the $1000 strike. These signals don’t just hint at sentiment—they scream at opportunity.

Bullish Calls at $1000 and the Battle for Investor Confidence

The options chain for LLY is clearly tilted toward a bullish bias. This Friday’s options show a staggering 4049 open interest on the $1000 call, far above any other strike. That’s not just noise—it’s a signal that many are pricing in a move past $1000 before the weekend. For context, the next highest call is the $950 at 1249 OI, and the $1100 at 1198. That suggests positioning is more aggressive than speculative.

On the put side, the $820 strike leads with 2028 OI. But with a put/call ratio of 1.17, the puts still outweigh the calls overall. This isn’t a pure bullish setup—it’s more like a cautious bet on a rebound, with hedging in case of a deeper pullback.

Block trading hasn’t shown any large whales moving on this day, which is interesting. That means the buildup in call options is coming from a broad base of traders, not just a single big player. That adds credibility to the idea of a potential short-term rally.

News as Fuel for the Bull Case

LLY’s recent news couldn’t be better for a bullish trade. The company just announced a $6.5B acquisition of Virentex, which is a big bet on the future of metabolic diseases. That kind of capital commitment signals confidence in its drug pipeline—and the market tends to reward that.

The FDA’s priority review of Donanemab, its Alzheimer’s drug, is another major catalyst. A mid-June decision could open the floodgates for a new revenue stream. And let’s not forget the $2B share buyback or the new manufacturing investments. These aren’t just headlines—they’re real money moves that can drive share price.

The downside? The lawsuit over ESG reporting and the supply chain warnings can’t be ignored. But with so many bullish catalysts and positioning in the $1000 call, I think the news is amplifying the options-driven trade more than it’s dampening it.

Actionable Trading Ideas for LLY

Let’s get to the good part. If you’re looking to play this, the two most compelling plays are:

• LLY20260403C1000: Buy this $1000 call expiring Friday. Why? Because it has the highest OI and is just $66.5 below the current price. If LLY can break above its 30-day support at ~914 and start closing higher, this could get a nice pop. Target: LLY closes above $980 by Friday.
• LLY20260410C1050: Buy this next-week $1050 call. It’s the top OI for next Friday and gives you a little more time for the news to play out. A strong bounce off the $930 intraday low could set up a short-term rally. Entry: 935–940. Target: $970 for a 3–5% move.

For stock traders, consider entering near $935 if support holds at the 30-day range (914–918). A clean close above $945 could confirm a breakout from the intraday selloff. Use $920 as a stop, and aim for a move up to $960 as the first target.

Volatility on the Horizon

We’re sitting at a pivotal moment for LLY. The news is bullish, the options are bullish, and the fundamentals are bullish. But the short-term chart is a mixed bag—MACD is crossing the signal line with a small positive histogram, and RSI is at 45, suggesting we’re not in overbought territory yet.

This isn’t a long-term buy—it’s a short-term bet with clear entry and exit points. But for the right trader with a clear risk plan, it’s a solid setup. If you can lock in a position before the market fully reacts to the news, the next few days could be very rewarding.

This is the kind of day where the market is giving you a map—and the first step is choosing to take it.